This is the second in a series of blogs outlining how to solve the logistics and packaging challenges involved in Cell & Gene Therapy. To read the first in the series, click here.
Imagine you're dealing with therapies that need to be kept colder than a winter's night in Antarctica. We're not just talking about a regular freezer; we mean -80°C or even diving into the chilling depths of ≤-150°C with liquid nitrogen.
Cell and gene therapy (CGT) is bringing us closer to treatments that once seemed like pure science fiction. But turning these advanced therapies into reality isn’t just about cutting-edge science. It also requires hospitals and clinics to be ready to handle them. For this reason, hospitals, clinics and apheresis centers must be qualified, certified and verified to ensure they have everything required to administer these advanced therapies.
That’s where manufacturers' site qualification teams come in. Manufacturing therapies is just the firs step; they must also ensure that hospitals, clinics, and infusion sites administering them have the proper training, equipment, and processes in place, and, crucially, that everything is documented accurately.
So, how do manufacturers qualify a site to become part of the CGT ecosystem? And what makes this process so uniquely challenging? Let’s break it down, focusing on packaging and logistics, because there's a lot that goes into site qualification, and we want to stay focused on the packaging and logistics aspects, leaving the lab coat people to do what they do best elsewhere.
Before a healthcare facility can start administering CGT treatments, manufacturers must ensure it's not just ready but truly equipped. This is an exhaustive evaluation of infrastructure, training and compliance to secure patient safety, uphold product quality, ensure efficacy and adhere to regulations.
The qualification process involves an on-site assessment, armed with a meticulous checklist that scrutinizes three critical areas:
In an ideal world, every site would be fully equipped and ready. But reality often requires a bit of hand-holding. Manufacturers should be prepared to provide specific instructions for handling their unique products or share expertise on packaging and logistics, such as how to pack-out insulated shippers correctly. So, let's dive into some of the biggest hurdles in qualifying sites and how manufacturers can navigate these challenges to ensure each therapy reaches its intended patient, maintaining both quality and efficacy.
As already mentioned, CGT products demand storage conditions capable of handling ultra-low emperatures. So the first consideraons must be: is the storage location secure, equipped with access control, and do monitoring systems with alarms exist to alert staff if there's a risk of a temperature excursion?
Even if an infusion site has the necessary freezers, does it have the correct racks to accommodate the product? A hospital might have racking, but will it fit your company's specific cryo-cassette or cryo-box? Manufacturers need to anticipate these gaps and be ready to provide customized solutions. This involves tackling some key logistical questions:
We must also include instructions for handling and moving these therapies around the hospital. Bags could be broken if not handled with care and precision; how far is the storage freezer from where the therapy will be thawed, from where the patient will be infused, and how will the bag or vial be moved around if there are longer distances and times involved? Does the hospital have the ability to move a frozen bag around on dry ice, playing 'keep the cold' to try and keep temperatures closer to ideal before thawing?
Where will shipments from the manufacturer be received, and how does this location relate to where the final product will be stored? Many condition monitoring systems rely on geolocation to trigger alerts and provide data on potential temperature excursions during transit. What happens if the hospital is a large campus, and the receiving dock for CGT products is more than a mile from where the product will be stored pre-infusion? CGT manufacturers must ensure they have accurate GPS coordinates for where the product is received, and that their ordering templates reflect this correctly.
And what if the hospital, clinic, or infusion site doesn't have the required storage freezers? Can the transport packaging itself serve as a temporary storage solution until the patient is ready for infusion? Some are exploring this to increase patient access, especially in remote locations or where specialized centers are scarce. How will that program work? Do the shippers get recharged with dry ice or LN2, or are replacement shippers sent to the hospital with the product then moved into the new shippers? Either way, this requires:
Procedures: We can’t just expect a nurse or technician to inherently know how to recharge a shipper or, if they're moving product from one shipper to another, how to properly pack the new shipper out. Also, these actions will need to be documented.
Training: Nurses and lab technicians will need to know when and how to recharge an LN2 dry vapor shipper or refill a dry ice shipper, or how to transfer product from one shipper to another without causing a temperature excursion or damaging the product.
With hospitals potentially handling multiple CGTs from different manufacturers, each with its own set of protocols, things can quickly getcomplex. Instead of having cold chain professionals in controlled warehouse environments, we've got hospitals and apheresis centers worldwide where nurses and lab techs – already juggling their primary roles – are now tasked with packing and shipping temperature-sensitive, irreplaceable patient cells.
To be clear, this is not a question of competence: nurses and lab techs do incredible work. But cold chain packaging and logistics is a specialized career field and, traditionally,, we train warehouse teams, not hospital staff managing a global array of CGT programs.
If you’ve ever designed a temperature-controlled packaging solution like we have here at CCT, you know how critical every detail is:
Getting the apheresis shipper pack-out just right while keeping it simple is crucial. Clear, language-agnostic training materials are a must, because sometimes, instructions don't translate well across languages or cultures. Many temperature excursions are more about poor pack-out design than actual temperature mishaps. Combine this with overly complex instructions, and the risks multiply.
Additionally, apheresis staff must be trained to inspect shippers before use. Even if the shipper is packed correctly, if it’s damaged or using expired components, the patient’s cells are at risk. Hospitals need backup shippers and components on-site, in a secure location for emergencies, and manufacturers must establish and have training on a system to replenish these supplies as they are used or expire. Getting sites set up with these materials and ensuring resupply in a timely manner is yet another critical aspect of site qualification.
Then, circling back to the scenario where sites use transport packaging as storage freezers, how will this program be set up? Training and procedures will be essential if manufacturers expect the infusion site to recharge LN2 or replenish dry ice. Similarly, there must be training on how to transfer product from one shipper to another if a new storage shipper is sent to replace one that's about to exhaust its LN2 or dry ice supply. Alongside this, comprehensive documentation is crucial to verify that all actions, from adding more refrigerant to moving product between shippers, are being executed correctly.
In the world of cell and gene therapy, deviations from the plan are inevitable, so contingency planning is essential.
Handling broken bags must be part of the training curriculum. Currently, the go-to method for shipping CAR-T therapies involves flexible IV bags, which are shipped at ≤-150°C in an aluminum cassette to avoid becoming brittle.
If a bag is broken, it doesn’t always mean the product is lost. Recovery procedures may be possible using a sterile recovery bag during thawing. Either way, clear communication between hospitals and manufacturers is vital to decide if a bag can be salvaged or if we need to send in the calvary with a backup bag, if there is even a backup bag available.
Then there’s the challenge of retrieving temperature data in transit. Sometimes, it’s as simple as a swift reboot but other times, retrieving temperature data requires returning the shipper to the LN₂ supplier for further analysis.
Effective site qualification requires seamless teamwork: hospitals working with the manufacture's customer service, customer service with quality and packaging engineering, and packaging engineering with suppliers.
And let’s not sleep on the magic of a supplier who gets these demands. Picking the right one is about locking in a partner who’s basically your supply chain and packaging team’s extra limb, ready to roll when challenges hit, andwho knows your business and operational quirks like the back of their hand.
Setting up robust, quick-response troubleshooting systems for both the expected and the unexpected is crucial. This ensures hospitals, treatment centers and clinics are fully equipped to support a successful CGT program, ready to tackle any deviation that comes their way.
5. Establishing Chain of Custody (CoC) and Chain of Identity (CoI)
Ensuring Chain of Custody (CoC) and Chain of Identity (CoI) is mandatory for compliance and crucial for safeguarding product integrity and patient safety. Hospitals must have clear protocols to track every step of the therapy's journey, from apheresis collection, through the handoff for transport to manufacturing, right up to receiving and the moment of infusion.
By implementing robust tracking and verification systems, manufacturers can ensure that CGT products reach the right patient in optimal condition, closing the loop on site qualification and safety.
Conclusion
Qualifying hospitals, clinics, and apheresis centers for cell and gene therapy is a necessary step to ensure the vein-to-vein triangle operates smoothly and supports successful patient treatment. These therapies aren't your typical treatments; they require facilities with high-tech infrastructure, comprehensive trainin and seamless coordination. From managing ultra-low temperature storage to navigating the complexities of handling protocols, apheresis logistics and emergency plans, every detail is crucial for maintaining therapy integrity and patient safety.
The challenges are significant, but so are the potential benefits. Through thorough site qualification, effective training, and addressing critical aspects like chain of custody and identity, manufacturers can help guide healthcare providers through the complexities of CGT administration. Success in this area goes beyond logistics, ultimately; ensuring each patient receives their therapy at the right time and in the right condition.